

S 1038

Drug Price Transparency in Medicaid Act of 2023

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Mar 29, 2023

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Mar 29, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/1038>

Sponsor

Name: Sen. Welch, Peter [D-VT]

Party: Democratic • **State:** VT • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Marshall, Roger [R-KS]	R · KS		Mar 29, 2023
Sen. Capito, Shelley Moore [R-WV]	R · WV		May 3, 2023
Sen. Gillibrand, Kirsten E. [D-NY]	D · NY		Apr 30, 2024

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Mar 29, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 3561	Related bill	Dec 17, 2024: Referred to the Subcommittee on Health.
118 HR 1613	Identical bill	Mar 24, 2023: Referred to the Subcommittee on Health.

Summary (as of Mar 29, 2023)

Drug Price Transparency in Medicaid Act of 2023

This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions and survey participation to be made publicly available.

Actions Timeline

- **Mar 29, 2023:** Introduced in Senate
- **Mar 29, 2023:** Read twice and referred to the Committee on Finance.